Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada.

ABSTRACT:

Introduction

This analysis compared the cost-effectiveness of once-daily regimens of mirabegron 50 mg and generic tolterodine ER 4 mg in a hypothetical cohort of previously treated patients with overactive bladder (OAB) in Canada.

Methods

A Markov model was developed to represent different health states according to OAB symptoms (frequency, incontinence), presence/absence of adverse events (AEs; dry mouth, constipation, blurred vision), and treatment status (on-treatment, discontinue treatment, restart previous treatment). The time horizon used was one year, with monthly transitions between health states. The model was populated using data from a phase 3, placebo-controlled trial of mirabegron that included tolterodine as an active comparator (SCORPIO), as well as other publ

SUBMITTER: Herschorn S 

PROVIDER: S-EPMC5434500 | biostudies-literature | 2017 Mar-Apr

REPOSITORIES: biostudies-literature